Subscribe
Business

News Summary: J&J seeks OK for resistant TB drug

By The Associated Press
Published
Add Washington Examiner on Google

NEW TB DRUG: Johnson & Johnson said Monday that it is seeking U.S. approval for the first new type of medicine to fight deadly tuberculosis in more than four decades. The experimental drug, called bedaquiline, would be the first medicine specifically for treating multi-drug-resistant tuberculosis.

THE DETAILS: The company is to begin late-stage testing this fall that will compare bedaquiline to dummy pills over nine months in about 600 patients; each will also take six other drugs that are the standard treatments for tuberculosis. That study is aimed at seeing whether treatment for resistant tuberculosis can be reduced to nine months from the current 18 to 24 months recommended by the World Health Organization.

Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.

Full midterm coverage.Deeper analysis.

Get unlimited access to Washington Examiner's reporting, expert analysis, and coverage of the midterm elections.

Get Unlimited Access

Cancel anytime.